CASIF
CASIF clinical trials: CASI Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where CASI Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 26
- Trials linked
- 25
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CASIF on the catalyst calendar · CASIF registry changes
- Primary completion Nov 30, 2028Sponsor estimatePhase 2NCT07946549A Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune ThrombocytopeniaCASI pharmaceuticals, Inc. · Chronic Immune ThrombocytopeniaNot yet recruitingCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2030Sponsor estimatePhase 1/Phase 2NCT07641426A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody...CASI pharmaceuticals, Inc. · Antibody Mediated RejectionRecruitingCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2026Sponsor estimatePhase 1/Phase 2NCT07017725A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune...CASI pharmaceuticals, Inc. · Chronic Immune ThrombocytopeniaRecruitingCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2018ActualPhase 2NCT02234986A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar CarcinomaCASI pharmaceuticals, Inc. · Advanced Adult Hepatocellular CarcinomaCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2023ActualPhase 1NCT04758767CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple MyelomaCASI pharmaceuticals, Inc. · Multiple MyelomaCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 8, 2021ActualPhase 4NCT06425276Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC TransplantationCASI Pharmaceuticals (China) Co., Ltd. · Multiple MyelomaCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2011ActualPhase 1NCT00806065Study of ENMD-2076 in Patients With Multiple MyelomaCASI pharmaceuticals, Inc. · Multiple MyelomaCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2010ActualPhase 1NCT00658671A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced CancerCASI pharmaceuticals, Inc. · Advanced CancerCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2017ActualPhase 2NCT01639248Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBCCASI pharmaceuticals, Inc. · Triple Negative Breast CancerCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2011ActualPhase 2NCT01104675Study of Oral ENMD-2076 Administered to Patients With Ovarian CancerCASI pharmaceuticals, Inc. · Ovarian CancerCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2011ActualPhase 2NCT00607607A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial CancerCASI pharmaceuticals, Inc. · Ovarian CancerCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2009ActualPhase 1/Phase 2NCT00408226Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung CancerCASI pharmaceuticals, Inc. · Advanced CancerCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2010ActualPhase 1NCT00904787Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological MalignanciesCASI pharmaceuticals, Inc. · Relapsed or Refractory Hematological MalignanciesCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2009ActualPhase 2NCT00568646Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic CancerCASI pharmaceuticals, Inc. · Pancreatic CancerCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2008ActualPhase 2NCT00444314Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell CarcinomaCASI pharmaceuticals, Inc. · Metastatic Renal Cell CarcinomaCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2008ActualPhase 2NCT00328497A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid TumorsCASI pharmaceuticals, Inc. · Carcinoid TumorCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2009ActualPhase 1NCT00656461Phase 1 Study of MKC-1 in Patients With Advanced CancerCASI pharmaceuticals, Inc. · Advanced CancerCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2008ActualPhase 2NCT00306631A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1CASI pharmaceuticals, Inc. · Breast CancerCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2009ActualPhase 1NCT00506402A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic MalignanciesCASI pharmaceuticals, Inc. · Hematological MalignanciesCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2008ActualPhase 2NCT00592579A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple MyelomaCASI pharmaceuticals, Inc. · Relapsed Multiple MyelomaCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 2NCT00049790Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell...CASI pharmaceuticals, Inc. · Carcinoma, Non-Small-Cell LungCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2007ActualPhase 2NCT00306618Safety and Efficacy Study of Panzem NCD to Treat GlioblastomaCASI pharmaceuticals, Inc. · Recurrent Glioblastoma MultiformeCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2007ActualPhase 2NCT00481455Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent...CASI pharmaceuticals, Inc. · Recurrent Glioblastoma MultiformeCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2008ActualPhase 2NCT00400348Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian CancerCASI pharmaceuticals, Inc. · Ovarian CancerCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2008ActualPhase 2NCT00394810Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate CancerCASI pharmaceuticals, Inc. · Prostate CancerCompletedCASIFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 1 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner